European journal of microbiology & immunology最新文献_第6页

Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review. 噬菌体疗法治疗耐甲氧西林金黄色葡萄球菌（MRSA）感染的疗效和临床潜力：综述。

European journal of microbiology & immunology Pub Date : 2024-02-02 Print Date: 2024-02-23 DOI: 10.1556/1886.2023.00064

Jamil Allen G Fortaleza, Christian Joseph N Ong, Rener De Jesus

{"title":"Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.","authors":"Jamil Allen G Fortaleza, Christian Joseph N Ong, Rener De Jesus","doi":"10.1556/1886.2023.00064","DOIUrl":"10.1556/1886.2023.00064","url":null,"abstract":"Staphylococcus aureus infections have already presented a substantial public health challenge, encompassing different clinical manifestations, ranging from bacteremia to sepsis and multi-organ failures. Among these infections, methicillin-resistant S. aureus (MRSA) is particularly alarming due to its well-documented resistance to multiple classes of antibiotics, contributing significantly to global mortality rates. Consequently, the urgent need for effective treatment options has prompted a growing interest in exploring phage therapy as a potential non-antibiotic treatment against MRSA infections. Phages represent a class of highly specific bacterial viruses known for their ability to infect certain bacterial strains. This review paper explores the clinical potential of phages as a treatment for MRSA infections due to their low toxicity and auto-dosing capabilities. The paper also discusses the synergistic effect of phage-antibiotic combination (PAC) and the promising results from in vitro and animal model studies, which could lead to extensive human clinical trials. However, clinicians need to establish and adhere to standard protocols governing phage administration and implementation. Prominent clinical trials are needed to develop and advance phage therapy as a non-antibiotic therapy intervention, meeting regulatory guidelines, logistical requirements, and ethical considerations, potentially revolutionizing the treatment of MRSA infections.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139673911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modelling of doxycycline-based prevention of bacterial sexually transmitted infections in comparison to condom-based and test-based prevention. 基于强力霉素的细菌性传播感染预防模型与基于安全套和检测的预防方法的比较。

European journal of microbiology & immunology Pub Date : 2024-01-30 Print Date: 2024-02-23 DOI: 10.1556/1886.2023.00059

Andreas Hahn, Hagen Frickmann, Ulrike Loderstädt

{"title":"Modelling of doxycycline-based prevention of bacterial sexually transmitted infections in comparison to condom-based and test-based prevention.","authors":"Andreas Hahn, Hagen Frickmann, Ulrike Loderstädt","doi":"10.1556/1886.2023.00059","DOIUrl":"10.1556/1886.2023.00059","url":null,"abstract":"Background: Doxycycline-based prevention of bacterial sexually transmitted infections (STIs) has been assessed in various studies and has been recommended by the European AIDS Clinical Society to be proposed to persons with repeated STIs on a case-by-case basis. However, while good preventive effects could be shown for Chlamydia trachomatis and Treponema pallidum in Europe, no reliable prevention against doxycycline resistance-affected bacterial causes of STIs like Neisseria gonorrhoeae and Mycoplasma genitalium was confirmed.Methods: In a modelling-approach, we assessed potential beneficial effects even against the latter microorganisms in case of optimized adherence with doxycycline prevention. These effects were modelled for Germany in comparison to traditional prevention schemes like condom-based STI-prevention and testing-as-prevention.Results: With estimated risk reduction in the ranges of 86% for N. gonorrhoeae and of 82% for Mycoplasma genitalium, expectable preventive efficacy similar to alternative preventive approaches could be calculated in case of optimized adherence with doxycycline prevention. In case of repeated risk exposure, the preventive potential of condom-based prevention was decreased compared to both optimized doxycycline prevention and testing-as-prevention.Conclusions: As suggested by the applied modelling, the preventive effect of optimized doxycycline prevention against bacterial STIs is in a similar range, like other common prevention strategies.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"50-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139577255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa - A literature review. 噬菌体疗法治疗耐多药铜绿假单胞菌引起的肺部感染--文献综述。

European journal of microbiology & immunology Pub Date : 2024-01-23 Print Date: 2024-02-23 DOI: 10.1556/1886.2023.00060

Vincent A Eiselt, Stefan Bereswill, Markus M Heimesaat

{"title":"Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa - A literature review.","authors":"Vincent A Eiselt, Stefan Bereswill, Markus M Heimesaat","doi":"10.1556/1886.2023.00060","DOIUrl":"10.1556/1886.2023.00060","url":null,"abstract":"Pulmonary infections of patients with cystic fibrosis (CF) or in intensive care units are frequently caused by the Gram-negative opportunistic pathogen Pseudomonas aeruginosa. Since these bacteria are commonly inherently multidrug-resistant (MDR) and hence, antibiotic treatment options are limited, bacteriophages may provide alternative therapeutic and prophylactic measures in the combat of pneumonia caused by P. aeruginosa. This prompted us to perform a comprehensive literature survey of current knowledge regarding effects of phages applied against pulmonary P. aeruginosa infections. The included 23 studies revealed that P. aeruginosa specific phages lyse and eliminate the bacteria even in case of biofilm production in vitro, whereas application to mice and men resulted in mitigated P. aeruginosa induced clinical signs and enhanced survival. Besides distinct host immune responses, no major adverse effects limiting therapeutic and/or prophylactic phage application were noted. However, the immune system and antibiotics generate synergies with phages due to the mutable sensitivity of P. aeruginosa. In conclusion, results summarized in this review provide evidence that phages constitute promising alternative treatment options for lung infections caused by MDR P. aeruginosa. Further studies are needed, however, to underscore the efficacy and safety aspects of phages application to infected patients including immune-compromised individuals.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"1-12"},"PeriodicalIF":0.0,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139522420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Better chance of survival is associated with higher neutrophil CD16 expression in patients with complicated intra-abdominal infections. 复杂腹腔内感染患者的存活几率与中性粒细胞 CD16 表达较高有关。

European journal of microbiology & immunology Pub Date : 2024-01-17 Print Date: 2024-02-23 DOI: 10.1556/1886.2023.00046

Evgeni Dimitrov, Krasimira Halacheva, Georgi Minkov, Emil Enchev, Yovcho Yovtchev

{"title":"Better chance of survival is associated with higher neutrophil CD16 expression in patients with complicated intra-abdominal infections.","authors":"Evgeni Dimitrov, Krasimira Halacheva, Georgi Minkov, Emil Enchev, Yovcho Yovtchev","doi":"10.1556/1886.2023.00046","DOIUrl":"10.1556/1886.2023.00046","url":null,"abstract":"Aim: The ability of neutrophil CD16 (nCD16) expression to predict outcome in complicated intra-abdominal infections (cIAIs) has not yet been studied; therefore we aimed to evaluate its potential prognostic value in such patients.Methods: Between November 2018 and August 2021 a single-center prospective study was performed in the Department of Surgical Diseases at a University Hospital Stara Zagora. A flow cytometry was used to measure the levels of nCD16 before surgery and on the 3rd postoperative day (POD) in 62 patients with cIAIs.Results: We observed a mortality rate of 14.5% during hospitalization. Survivors had significantly higher perioperative expression of nCD16 than non-survivors (P = 0.02 preoperatively and P = 0.006 postoperatively). As predictor of favorable outcome we found a good predictive performance of preoperative nCD16 (AUROC = 0.745) and a very good predictive performance of postoperative levels (AUROC = 0.846). An optimal preoperative threshold nCD16 = 34.75 MFI permitted prediction of survival with sensitivity and specificity of 66.7% and 77.8%, respectively. A better sensitivity of 72.5% and specificity of 85.7% were observed for threshold = 54.8 MFI on the 3rd POD.Conclusion: Perioperative neutrophil CD16 expression shows a great potential as a predictor of favorable outcome in patients with cIAIs.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between ABO and Rh blood groups and Toxoplasma gondii infection: A cross sectional study. ABO 和 Rh 血型与弓形虫感染的关系：一项横断面研究。

European journal of microbiology & immunology Pub Date : 2024-01-12 Print Date: 2024-02-23 DOI: 10.1556/1886.2023.00052

Alma Rosa Pérez-Álamos, Marisela Aguilar-Durán, Sergio Estrada Martínez, Agar Ramos-Nevárez, Carlos Alberto Guido-Arreola, Antonio Sifuentes-Álvarez, Sandra Margarita Cerrillo-Soto, Raúl Graciano Ibarra, Cosme Alvarado-Esquivel

{"title":"Association between ABO and Rh blood groups and Toxoplasma gondii infection: A cross sectional study.","authors":"Alma Rosa Pérez-Álamos, Marisela Aguilar-Durán, Sergio Estrada Martínez, Agar Ramos-Nevárez, Carlos Alberto Guido-Arreola, Antonio Sifuentes-Álvarez, Sandra Margarita Cerrillo-Soto, Raúl Graciano Ibarra, Cosme Alvarado-Esquivel","doi":"10.1556/1886.2023.00052","DOIUrl":"10.1556/1886.2023.00052","url":null,"abstract":"We aimed to determine the association between the seropositivity to Toxoplasma gondii and the ABO and Rh blood groups in 2,053 people. ABO and Rhesus blood groups and anti-T. gondii IgG and IgM antibodies were determined using commercially available assays. Of the 2,053 people studied, 171 (8.3%) were positive for anti-T. gondii IgG antibodies. Sixty-five (38.0%) and 36 (21.1%) of these 171 individuals had high anti-T. gondii IgG antibody levels (≥150 IU mL-1) and anti-T. gondii IgM antibodies, respectively. We found the following prevalences of T. gondii infection among the ABO groups: 8.5% in group A, 4.3% in group B, 4.7% in group AB, and 8.9% in group O (P = 0.19). The prevalences of T. gondii infection among Rh groups were: 8.4% in the Rh-positive group and 7.1% in the Rh-negative group (P = 0.58). Logistic regression analysis showed that the frequencies of ABO and Rh blood groups were similar (P > 0.05) among people with positive and negative serology for anti-T. gondii IgG antibodies, with high (≥150 IU mL-1) and lower (<150 IU mL-1) levels of anti-T. gondii IgG antibodies, and with positive and negative serology for anti-T. gondii IgM antibodies. Results does not support an association between T. gondii infection and ABO and Rh blood groups.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139428091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic oral application of resveratrol to alleviate acute campylobacteriosis in human gut microbiota associated IL-10-/- mice. 预防性口服白藜芦醇可缓解与人类肠道微生物群相关的 IL-10-/- 小鼠的急性弯曲杆菌病。

European journal of microbiology & immunology Pub Date : 2023-12-15 Print Date: 2023-12-21 DOI: 10.1556/1886.2023.00042

Markus M Heimesaat, Niklas Schabbel, Luis Q Langfeld, Nizar W Shayya, Soraya Mousavi, Stefan Bereswill

{"title":"Prophylactic oral application of resveratrol to alleviate acute campylobacteriosis in human gut microbiota associated IL-10-/- mice.","authors":"Markus M Heimesaat, Niklas Schabbel, Luis Q Langfeld, Nizar W Shayya, Soraya Mousavi, Stefan Bereswill","doi":"10.1556/1886.2023.00042","DOIUrl":"10.1556/1886.2023.00042","url":null,"abstract":"Human infections with the food-borne zoonotic enteropathogen Campylobacter jejuni are increasing globally. Since multi-drug resistant bacterial strains are further on the rise, antibiotic-independent measures are needed to fight campylobacteriosis. Given its anti-microbial and anti-inflammatory properties the polyphenolic compound resveratrol constitutes such a promising candidate molecule. In our present placebo-controlled intervention trial, synthetic resveratrol was applied perorally to human gut microbiota-associated (hma) IL-10-/- mice starting a week before oral C. jejuni infection. Our analyses revealed that the resveratrol prophylaxis did not interfere with the establishment of C. jejuni within the murine gastrointestinal tract on day 6 post-infection, but alleviated clinical signs of campylobacteriosis and resulted in less distinct colonic epithelial apoptosis. Furthermore, oral resveratrol dampened C. jejuni-induced colonic T and B cell responses as well as intestinal secretion of pro-inflammatory mediators including nitric oxide, IL-6, TNF-α, and IFN-γ to basal levels. Moreover, resveratrol application was not accompanied by significant shifts in the colonic commensal microbiota composition during campylobacteriosis in hma IL-10-/- mice. In conclusion, our placebo-controlled intervention study provides evidence that prophylactic oral application of resveratrol constitutes a promising strategy to alleviate acute campylobacteriosis and in consequence, to reduce the risk for post-infectious autoimmune sequelae.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"135-149"},"PeriodicalIF":0.0,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138813548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Campylobacter in Africa - A specific viewpoint. 非洲的弯曲杆菌--一种特殊观点。

European journal of microbiology & immunology Pub Date : 2023-12-05 Print Date: 2023-12-21 DOI: 10.1556/1886.2023.00043

Ellis Kobina Paintsil, Wycliffe O Masanta, Annika Dreyer, Leonid Ushanov, Stella I Smith, Hagen Frickmann, Andreas E Zautner

{"title":"Campylobacter in Africa - A specific viewpoint.","authors":"Ellis Kobina Paintsil, Wycliffe O Masanta, Annika Dreyer, Leonid Ushanov, Stella I Smith, Hagen Frickmann, Andreas E Zautner","doi":"10.1556/1886.2023.00043","DOIUrl":"10.1556/1886.2023.00043","url":null,"abstract":"Campylobacter infections and campylobacteriosis-associated post-infectious sequelae are a significant global health burden that needs to be addressed from a specific African perspective. We conducted a comprehensive literature search on NCBI PubMed to compile a comprehensive narrative review article on Campylobacter infections in Africa, focusing on key aspects in human and veterinary medicine as well as food hygiene. We specifically focused on the epidemiology of enteropathogenic Campylobacter spp. in sub-Saharan and North Africa considering antimicrobial susceptibility. The most significant sequela resulting from molecular mimicry to Campylobacter surface structures is the Guillain-Barré syndrome, which was mainly examined in the context of limited studies conducted in African populations. A dedicated subsection is allocated to the limited research on the veterinary medically important species Campylobacter fetus. There are significant differences in the composition of the gut microbiome, especially in rural areas, which affect the colonization with Campylobacter spp. and the manifestation of campylobacteriosis. There may be a problem of overdiagnosis due to asymptomatic colonization, particularly in the detection of Campylobacter using molecular biological techniques. To reduce the colonization and infection rate of Campylobacter, we propose implementing several control measures and urge further research to improve the current understanding of the peculiarities of campylobacteriosis in Africa.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"107-124"},"PeriodicalIF":0.0,"publicationDate":"2023-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138489399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Actinomyces spp. and related organisms in the development of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on a case series. 放线菌及其相关生物在药物相关性颌骨骨坏死(MRONJ)发展中的作用:基于病例系列的临床证据。

European journal of microbiology & immunology Pub Date : 2023-12-01 Print Date: 2023-12-21 DOI: 10.1556/1886.2023.00041

Zsanett Kövér, Ágnes Bán, Márió Gajdács, Beáta Polgár, Edit Urbán

{"title":"Role of Actinomyces spp. and related organisms in the development of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on a case series.","authors":"Zsanett Kövér, Ágnes Bán, Márió Gajdács, Beáta Polgár, Edit Urbán","doi":"10.1556/1886.2023.00041","DOIUrl":"10.1556/1886.2023.00041","url":null,"abstract":"Medication-related osteonecrosis of the jaw (MRONJ) is an increasingly common consequence of antiresorptive treatment, which often leads to the development of necrotic exposed bone surfaces with inflammatory processes affecting the jawbone. Although the development of MRONJ is often associated with the inflammatory response or infections caused by the colonizing members of the oral microbiota, the exact pathogenesis of MRONJ is still not fully understood. In the present paper, we aimed to provide additional, microbiological culture-supported evidence, supporting the \"infection hypothesis\" that Actinomyces spp. and related organisms may play an important pathogenic role in the development of MRONJ and the resulting bone necrosis. In our case series, all patients presented with similar underlying conditions and anamnestic data, and have received antiresorptive medications (bisphosphonates or a RANK ligand (RANKL) inhibitor) to prevent the occurrence or progression of bone metastases, secondary to prostate cancer. Nevertheless, a few years into antiresorptive drug therapy, varying stages of MRONJ was identified in the mentioned patients. In all three cases, quantitative microbiological culture of the necrotic bone samples yielded a complex microbiota, dominated by Actinomyces and Schaalia spp. with high colony counts. Additionally, our followed-up case series document the treatment of these patients with a combination of surgical intervention and long-term antibiotic therapy, where favourable clinical responses were seen is all cases. If the \"infection hypothesis\" is valid, it may have significant consequences in the preventative and therapeutic strategies associated with this disease.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"125-134"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138465153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral application of carvacrol, butyrate, ellagic acid, and 2'-fucosyl-lactose to mice suffering from acute campylobacteriosis - Results from a preclinical placebo-controlled intervention study. 口服香芹酚、丁酸、鞣花酸和2′-焦酰基乳糖治疗急性弯曲菌病小鼠——临床前安慰剂对照干预研究结果

European journal of microbiology & immunology Pub Date : 2023-11-21 Print Date: 2023-11-23 DOI: 10.1556/1886.2023.00037

Soraya Mousavi, Lia V Busmann, Rasmus Bandick, Nizar W Shayya, Stefan Bereswill, Markus M Heimesaat

{"title":"Oral application of carvacrol, butyrate, ellagic acid, and 2'-fucosyl-lactose to mice suffering from acute campylobacteriosis - Results from a preclinical placebo-controlled intervention study.","authors":"Soraya Mousavi, Lia V Busmann, Rasmus Bandick, Nizar W Shayya, Stefan Bereswill, Markus M Heimesaat","doi":"10.1556/1886.2023.00037","DOIUrl":"10.1556/1886.2023.00037","url":null,"abstract":"Background: Acute campylobacteriosis caused by oral infections with the enteropathogen Campylobacter jejuni represent serious threats to global human health. Since novel treatment options with safe and antibiotics-independent compounds would be highly appreciable, we here investigated the anti-bacterial and disease-alleviating effects of carvacrol, butyrate, ellagic acid, and 2'-fucosyl-lactose in acute murine campylobacteriosis. To address this, secondary abiotic IL-10-/- mice were perorally infected with C. jejuni and treated with either compound alone or all four in combination via the drinking water starting two days post-infection.Results: On day 6, the duodenal pathogen loads were lower in mice of the combination versus the vehicle treatment cohort. Importantly, mice treated with carvacrol and the combination presented with less distinct diarrheal symptoms, colonic histopathology, epithelial cell apoptosis, and immune cell responses when compared to vehicle counterparts on day 6 post-infection. Furthermore, the combination treatment did not only diminish colonic IFN-γ, TNF-α, and IL-6 secretion in C. jejuni infected mice, but also dampened extra-intestinal and even systemic pro-inflammatory cytokine concentrations to basal levels as measured in liver, kidneys, lungs, and serum samples.Conclusions: Our preclinical placebo-controlled intervention trial provides evidence that the combined oral application of carvacrol, butyrate, ellagic acid, and 2'-fucosyl-lactose alleviates acute campylobacteriosis in the vertebrate host.","PeriodicalId":93998,"journal":{"name":"European journal of microbiology & immunology","volume":" ","pages":"88-105"},"PeriodicalIF":0.0,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxoplasma gondii infection of the central nervous system and suicide: A case-control study of decedents. 刚地弓形虫感染中枢神经系统与自杀:死者病例对照研究。

European journal of microbiology & immunology Pub Date : 2023-11-20 Print Date: 2023-11-23 DOI: 10.1556/1886.2023.00033

Laura Alejandra Mendoza-Larios, Fernando García-Dolores, Luis Francisco Sánchez-Anguiano, Elizabeth Irasema Antuna-Salcido, Jesús Hernández-Tinoco, Adriana Rocha-Salais, Marcela Araceli Segoviano-Mendoza, Antonio Sifuentes-Álvarez, Cosme Alvarado-Esquivel

引用次数: 0